Sarepta Therapeutics short interest was 32.62% of the float on June 30th, according to new data we received from Benzinga. Short interest totaled 28,734,169 shares, which was an increase of 14.17% from June 15th.
It is estimated that it would take 5.75 days for short sellers to buy back their shares, with current trading volumes.
Sarepta Therapeutics Hedge Fund Activity
We have seen 137 institutional investors add shares of Sarepta Therapeutics stock to their portfolio, and 160 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 3,902,596 shares (+inf%) to their portfolio in Q1 2026, for an estimated $84,920,488
- TWO SIGMA INVESTMENTS, LP added 2,151,740 shares (+88.1%) to their portfolio in Q1 2026, for an estimated $46,821,862
- FIRST TRUST ADVISORS LP added 2,143,211 shares (+107.6%) to their portfolio in Q1 2026, for an estimated $46,636,271
- AQR CAPITAL MANAGEMENT LLC removed 1,363,423 shares (-17.5%) from their portfolio in Q1 2026, for an estimated $29,668,084
- CANADA PENSION PLAN INVESTMENT BOARD added 895,971 shares (+258.3%) to their portfolio in Q1 2026, for an estimated $19,496,328
- MORGAN STANLEY added 684,358 shares (+35.8%) to their portfolio in Q1 2026, for an estimated $14,891,630
- LEGAL & GENERAL GROUP PLC added 602,286 shares (+227.7%) to their portfolio in Q1 2026, for an estimated $13,105,743
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Sarepta Therapeutics Insider Trading Activity
Sarepta Therapeutics insiders have traded $SRPT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SRPT stock by insiders over the last 6 months:
- STEPHEN MAYO sold 7,239 shares for an estimated $123,207
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Sarepta Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Underperform" rating on 03/26/2026
To track analyst ratings and price targets for Sarepta Therapeutics, check out Quiver Quantitative's $SRPT forecast page.
Sarepta Therapeutics Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 8 analysts offer price targets for $SRPT in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Andy Chen from Wolfe Research set a target price of $27.0 on 07/09/2026
- Biren Amin from Piper Sandler set a target price of $20.0 on 07/09/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $5.0 on 04/16/2026
- Yigal Nochomovitz from Citigroup set a target price of $13.0 on 03/26/2026
- Kostas Biliouris from Oppenheimer set a target price of $37.0 on 03/19/2026
- Uy Ear from Mizuho set a target price of $31.0 on 03/13/2026
- Yanan Zhu from Wells Fargo set a target price of $38.0 on 02/27/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
